A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.

[1]  K. Weber,et al.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  O. Lambotte,et al.  Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. , 2019, JAMA oncology.

[3]  Ayumu Takeno,et al.  Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report , 2019, BMC Endocrine Disorders.

[4]  P. Chanson,et al.  French Endocrine Society Guidance on endocrine side effects of immunotherapy , 2018, Endocrine-related cancer.

[5]  F. Hodi,et al.  Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. , 2018, Endocrine reviews.

[6]  R. Sullivan,et al.  High‐dose glucocorticoids for the treatment of ipilimumab‐induced hypophysitis is associated with reduced survival in patients with melanoma , 2018, Cancer.

[7]  G. Long,et al.  The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. , 2018, European journal of endocrinology.

[8]  W. Barry,et al.  Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis , 2017, JAMA Oncology.

[9]  E. Plimack,et al.  Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. , 2017, Cancer treatment reviews.

[10]  K. Kerr,et al.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Cosottini,et al.  Hypophysitis Secondary to Cytotoxic T-Lymphocyte-Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series. , 2016, The American journal of pathology.

[12]  S. Ryu,et al.  Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy , 2016, Nature Communications.

[13]  M. Murad,et al.  Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[14]  P. Carroll,et al.  Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review , 2016, Clinical endocrinology.

[15]  D. Rodríguez-Abreu,et al.  Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. , 2016, The oncologist.

[16]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American journal of clinical oncology.

[17]  Wei Zhou,et al.  Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.

[18]  J. Grob,et al.  Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. , 2015, European journal of endocrinology.

[19]  A. Giobbie-Hurder,et al.  Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study , 2014, Clinical Cancer Research.

[20]  Antoni Ribas,et al.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.

[21]  S. H. van der Burg,et al.  Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response , 2014, Science Translational Medicine.

[22]  R. Sullivan,et al.  Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. , 2014, The Journal of clinical endocrinology and metabolism.

[23]  A. Korman,et al.  In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates , 2014, Cancer Immunology Research.

[24]  J. Wolchok,et al.  Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.

[25]  J. Wolchok,et al.  Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. , 2014, Endocrine-related cancer.

[26]  M. Postow,et al.  Checkpoint blocking antibodies in cancer immunotherapy , 2014, FEBS letters.

[27]  P. Marchetti,et al.  Endocrine side effects induced by immune checkpoint inhibitors. , 2013, The Journal of clinical endocrinology and metabolism.

[28]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[29]  I. Lowy,et al.  Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[30]  S. Steinberg,et al.  Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[31]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[32]  S. Corsello,et al.  Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. , 2012, The oncologist.

[33]  L. Walker,et al.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses , 2011, Nature Reviews Immunology.

[34]  J. Wolchok,et al.  9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs) , 2009 .

[35]  田攀文,et al.  Autoimmune hypophysitis , 2007 .

[36]  S. Rosenberg,et al.  Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma , 2006, Journal of immunotherapy.

[37]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Lanfranco,et al.  CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms , 2004, Molecular and Cellular Biology.

[39]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[40]  C. Yedinak,et al.  Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes , 2009, Pituitary.

[41]  A. Olivi,et al.  Autoimmune hypophysitis. , 2020, Endocrine reviews.